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meta-iodobenzylguanidine (MIBG) is a multipotent drug which is
increasingly applied in clinical oncology. As a derivative of the
neuron-blocking agents bretylium and guanethidine, radio-
iodinated [131]MIBG has been primarily developed for the scinti-
graphic detection of neuroadrenergic tissues (Wieland et al, 1980).
Subsequently, [131]MIBG has been used at elevated radioactive
doses for endo-irradiation of neuroadrenergic neoplasms such as
phaeochromocytoma and neuroblastoma (Sisson and Wieland,
1986; Hoefnagel et al, 1987 a). The accumulation of MIBG in
normal and neoplastic tissues of neuroadrenergic origin is based
on its affinity for the specific uptake-1 mechanism of catechol-
amines (Jaques et al, 1987; Smets et al, 1991). Because of cross-
affinity for the serotonin transporter (Rutgers et al, 1993),
[131l]MIBG is also applied for diagnosis and treatment of carcinoid
tumours (Hoefnagel et al, 1987b; Taal et al, 1996a).
In the course of clinical investigations, non-radiolabelled MIBG
is administered as a pre-dose to improve the tumour uptake and
retention of a subsequent [131l]MIBG dose (Taal et al, 1996b;
Hoefnagel et al, 1998). Moreover, non-radiolabelled MIBG
induces long-lasting palliative responses of the carcinoid
syndrome in 60% of the patients, similar to those obtained with
targeted radiotherapy with [131l]MIBG (Taal et al, 1996a). This
syndrome, with episodes of diarrhoea, flushing, wheezing,
vomiting and/or palpitations, and in several cases the ultimate
development of lethal cardiac failure, is due to high production
and sudden release of vasoactive compounds, predominantly sero-
tonin, from liver metastases. Despite the subjective improvement,
neither tumour regression nor decreases in urinary levels of the
serotonin metabolite 5-HIAA were observed. For palliative treat-
ment unlabelled MIBG is preferred over [131l]MIBG therapy, espe-
cially in elderly patients or patients in poor condition, because no
isolation is needed (Taal et al, 1996a).
Although the mechanism of palliation by MIBG is unknown,
pharmacological effects on serotonin storage or release, or effects
at the level of the serotonin 5-HT receptor are most probable.
However, contributions of mitochondrial inhibition by MIBG
observed in vitro (Loesberg et al, 1990a) and in vivo (Kuin et al,
1994), vascular effects by inhibition of nitric oxide synthase
(NOS) (Kuin et al, 1998) or interference with mono(ADP)ribosyl-
ation (Loesberg et al, 1990b), cannot be excluded.
Side-effects attributable to unlabelled MIBG in patients are
transient changes in blood pressure and pallor, which are dose-
limiting but disappear shortly after the end of the infusion (Taal 
et al, 1996a). In mice, i.v. administered MIBG is acutely lethal
at a bolus injection of > 25 mg kg–1 (M. Rutgers, unpublished
results). After i.p. administration, MIBG appeared to be lethal 
at single doses of just over 40 mg kg–1 MIBG, but not at 
40 mg kg–1 for 9 sequential days (Smets et al, 1988). Side-effects
encountered above 30 mg kg–1 i.p. are stress-related, sympatho-
mimetic effects, plausibly explained by the release of bioamines
from their storage granules (Kuin et al, 1994), and reduced renal
clearance rates accompanied by histological tubular damage (Kuin
et al, 1998).
In patients, MIBG administered in an oral formulation might
maintain palliation of the carcinoid syndrome without need for
hospitalization. Moreover, MIBG might prevent the acute side-
effects associated with i.v. infusion, allowing higher doses, which
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may increase the percentage of responders. Because of multiple
biochemical effects, gastrointestinal toxicity is of concern with
this route of administration. In addition, MIBG, with a lipophilic
benzyl group and a positively charged diamine group at physio-
logical pH, is a typical organic cation and thus a potential substrate
for P-glycoprotein-mediated export in the gastrointestinal tract.
Adequate absorption, therefore, may be limited as demonstrated
for paclitaxel (Sparreboom et al, 1997). Moreover, biodistribution
of oral MIBG may vary considerably for oral and i.v. routes.
In the present study, we have explored the feasibility of oral
administration of MIBG by studying the bioavailability and
biodistribution of [125l]MIBG in C3H/Km mice. Moreover, renal
function and administration route-related toxicity were examined
after single and repeated oral administration.
MATERIALS AND METHODS
Animals and treatment protocols
The animal experiments were carried out in accordance with
protocols approved by the experimental animal welfare committee
of the institute and conform to national and European legislation
for animal experimentation. In all experiments C3H/Km male
mice were used at an age of 10–12 weeks, weighing 28–35g.
MIBG. 1/2 H2SO4 (EMKA Chemie, Germany) was dissolved in
phosphate-buffered saline (PBS) and administered orally at doses
of up to 80mg kg–1 with the aid of a blunt needle. Intravenous
injection of 15mg kg–1 MIBG, which appeared to be just below
the maximal tolerated dose in this strain of mice, required slow
administration over approximately 1min. For repeated oral
administration animals were treated daily with 40mgkg–1 for
5 sequential days or 20mg kg–1 for two courses of 5 days with a
2-day interval. All administrations were given in a volume of
0.01ml g–1 body weight and controls received a corresponding
volume of PBS.
Mice were withheld from food 10–12h before single treatment
and 5h before the daily administration. Water was available ad
libitum.
Biodistribution and bioavailability
[125l]MIBG (specific activity 740–925MBq mg–1 was synthesized
as described previously (Wieland et al, 1980) and prepared to a
specific activity of 0.27MBq mg–1 by addition of unlabelled MIBG
for i.v. or p.o. treatment with 15mg kg–1 (0.11MBq mouse–1). After
10 and 30min and 1, 4 and 24h, blood was taken from the carotid
artery under ether anaesthesia and mice were sacrificed. At each
time point, four animals were used. Because MIBG is, at least in
humans, metabolized to only a minor degree (Wafelman et al.
1994), [125l]MIBG levels could be determined by gamma-counting
of 100ml of blood, 100ml of plasma, the kidneys, liver and about 
2cm of the small intestine (at 1cm distance of the stomach and
flushed by PBS), which were expressed as percentage of the
injected dose per ml of plasma or gram tissue. MIBG retained by
the total body was calculated by adding the counts of the remaining
body, corrected by 10/9 for differences in counting efficiency, to
the counts of the excised tissues and expressed as percentage of
total dose. Areas under the concentration–time curve (AUCs) were
calculated by the trapezoidal rule with extrapolation to infinity and
bioavailability in plasma by the formula AUC p.o./AUC i.v. ´
100%. The mean residence time (MRT) was calculated by dividing
the area under the moment curve (AUMC) by the AUC. Clearance
(Cl) and volume of distribution (Vd) were determined for i.v.
administration only by the formulas Cl = dose/AUC and Vd = Cl ´
MRT respectively. Because plasma concentrations were calculated
as % dose ml–1 plasma, the AUC was determined as h % dose ml–1.
Renal function
Renal function was measured by determination of the glomerular
filtration of [51Cr]EDTA as described previously (Kuin et al,
1998). In short, [51Cr]EDTA (0.37MBq 100ml–1, specific activity
37–74MBq mg–1; Amersham International, UK) was injected 
4.5h after single dose MIBG or 1 day after repeated MIBG admin-
istration. After 30min, blood samples were taken from the retro-
orbital sinus and the mice were sacrificed. Plasma [51Cr]EDTA
levels were determined by gramma-counting and expressed as
percentage of injected dose per ml plasma. Increases in residual
plasma [51Cr]EDTA levels above control values reflect reduced
renal clearance.
Toxicity and histological examination
After oral injection of MIBG, mice were weighed daily and
checked for visible signs of illness. Mice were sacrificed at 5h,
24h and 7, 14 and 48 days after single dose, and 1 day after the
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Figure 1[125l]MIBG levels in plasma (A) and total body (B) after i.v. (ll) or
oral (l) administration of 15mg kg–1. Mean values ±s.d. (n = 4). Error bars if
not shown are within the size of the symbols804 A Kuin et al
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last dose of the repeated administration. Dissected organs were
routinely processed for histological examination by an animal
pathologist.
RESULTS
Biodistribution
The bioavailability of orally administered MIBG was determined
at 15 mg kg–1, which is near to the maximal tolerated dose of i.v.-
administered MIBG in C3H/Km mice. Based on the AUCs
presented in Figure 1 A, the bioavailability of orally administered
MIBG was calculated to be 59%. Based on i.v. MIBG administra-
tion the clearance (Cl) was calculated to be 178 ml h–1 kg–1, the Vd
43.6 ml and the MRT 8.9 h. After oral administration the MRT was
5.8 h. The AUC of the total body was the same for both adminis-
tration routes (Figure 1 B). Tissue levels after orally administered
MIBG were higher for liver and small intestine but lower for the
kidney as compared with i.v. administration (Table 1). These
differences were observed during the first 4 h only, as illustrated
for small intestine and kidney in Figure 2.
Toxicity of a single dose MIBG
MIBG could be given orally up to 60 mg kg–1 without lethality.
Although at 50 and 60 mg kg–1 mean values are not significantly
different from controls (P > 0.05) some animals demonstrated a
decreased renal clearance (Figure 3). MIBG (80 mg kg–1) severely
impaired renal clearance in two mice and was acutely lethal to a third.
Renal damage was observed by histological analysis 5 and 24 h
after treatment with 50 and 60 mg kg–1 and had recovered after 7
days, similar to what was described for i.p.-administered MIBG
(Kuin et al, 1998). The damage was observed as acute degenera-
tion and vacuolization of renal epithelial cells of the cortico-
medullar tubules, dilatation, most prominent in the distal tubuli,
and minor hypertrophy of the epithelium of Bowman’s capsule.
No histological abnormalities were observed in stomach,
intestines, liver, pancreas, bladder, spleen, heart, lungs, thymus,
salivary glands, brain and testes up to 48 days after treatment.
Also, body weights of treated mice were not different from PBS-
treated controls and no visible signs of illness were observed.
Renal function and toxicity after repeated oral
administration
MIBG was administered at 40 mg kg–1 over 5 sequential days or at
20 mg kg–1 in two courses of 5 days with a 2-day interval. Neither
schedule affected body weight in comparison with PBS-treated
controls. No visible signs of illness were observed, but mice reacted
more alertly and were slightly more stressed than PBS-treated
Table 1 Relative exposure to orally administered MIBG (15 mg kg–1)
Tissue AUC p.o./AUC i.v. ´ 100%
Plasma 59
Blood 63
Kidney 79
Liver 123
Small intestine 165
Total body 108
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Figure 2 [125l]MIBG levels in small intestine (A) and kidney (B) during the
first 4 h after i.v. (l l) or oral (l) administration of 15 mg kg–1. Mean values
± s.d. (n = 4). Error bars if not shown are within the size of the symbols
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Figure 3 Renal clearance expressed by residual [51Cr]EDTA plasma levels
5 h after single oral MIBG treatment. Controls received a corresponding
volume of PBS. Symbols represent results of individual mice in three
independent experimentsOral administration of MIBG 805
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mice. No change in renal clearance was observed 1 day after the
last treatment. Residual [51Cr]EDTA levels per ml plasma were 
2.5 ± 0.3% for controls and 2.1 ± 0.4% for 40 mg kg–1 MIBG, and
2.2 ± 0.6% for controls and 1.6 ± 0.5% for 20 mg kg–1 MIBG, at
days 5 and 12 respectively (n = 6).
Parallel histological examination revealed the absence of renal
damage and of abnormalities in stomach, intestines, liver, heart,
lungs, thymus, salivary glands and testes. In the spleen, hyper-
aemia of the red pulp was observed after both protocols, which
was not observed after a single dose of 60 mg kg–1.
DISCUSSION
Non-radiolabelled MIBG has increasing clinical potential (Taal et
al, 1996a). In the palliation of the carcinoid syndrome MIBG is
effective as a single dose but might require chronic drug adminis-
tration for maintenance. For this purpose we investigated the feasi-
bility of oral administration. We demonstrated a bioavailability of
59% after oral administration in mice. The absorption of MIBG
was fast and highest plasma levels were observed only 5 min after
oral administration, indicating that P-glycoprotein-mediated
export of MIBG into the intestinal lumen is of minor importance.
Plasma and total body MIBG clearance rates were similar for both
administration routes (Figure 1). As a result of these similar clear-
ance rates and the absence of a slow-release effect after oral
administration, the MRT of MIBG is shorter after oral administra-
tion than after i.v. injection. The oral administration routes caused
a shift in the biodistribution, mainly into the intestine and liver
(Figure 2 and Table 1), without affecting total body clearance.
This, however, does not reflect first-pass metabolism as MIBG is
metabolized only to a minor degree (Wafelman et al, 1994).
Despite a relatively high exposure to the small intestine and liver,
no ulceration or other histological damage were observed in these
tissues or in the stomach at the MTD. Because of the adequate
bioavailability and absence of route-related toxicity, we consider
MIBG a suitable compound for further clinical research of the oral
administration route.
Side-effects of oral MIBG administration, encountered at 
³ 50 mg kg–1, were transient histological tubular damage accom-
panied in some mice by a reduced renal clearance (Figure 3).
These results were similar to those of previous studies demon-
strating renal toxicity after i.p. administration of high-dose MIBG,
most probably because of the direct toxic effects of MIBG, present
in high concentrations in the primary urine (Kuin et al, 1998). In
contrast, repeated oral administration of MIBG up to accumulated
doses of 200 mg kg–1 did not induce histological damage of the
kidney or other tissues. The absence of cumulative effects agrees
with a previous study demonstrating absence of acute toxicity after
repeated treatment at the maximum tolerated dose (Smets et al,
1988), and may be attributed to rapid clearance of the drug (Figure
1B). Hyperaemia of the spleen is probably due to vascular effects
as a result of MIBG-induced bioamine release (Kuin et al, 1994) or
vasodilatation by inhibition of NOS (Kuin et al, 1998).
The maximal tolerated dose of a single dose of 60 mg kg–1 for
orally administered MIBG was 3–4 times higher than that for
bolus i.v. administration. At the maximal tolerated doses the
plasma AUC of MIBG will therefore be higher for the oral than for
the i.v. administration. Assuming a dose–response relationship,
oral application might consequently increase the response rate in
patients with carcinoid syndrome. MIBG was injected i.v. in rela-
tive low doses to prevent acute effects of high peak levels. In
patients, these acute effects are partly prevented by slow infusion,
which will reduce the gain in AUC after oral administration
compared with the animal studies. On the other hand, because
carcinoid tumours and their metastases are mainly located in the
intestines and liver, the relatively high levels of MIBG in these
tissues after oral administration might be an additional advantage
in targeting these tumour localizations.
In carcinoid patients, side-effects of i.v.-administered MIBG are
encountered at a dose of 34 mg m–2 (Taal et al, 1996a), much lower
than that observed in a phase I trial in patients with non-carcinoid
tumours (135 mg m–2, B. Taal, personal communication). This
difference is most probably attributable to a MIBG-induced
release of vasoactive compounds, such as serotonin, stored by the
carcinoid tumour. Although it could be argued therefore that dose
escalation is not a primary goal for improved response rates, our
previous study has demonstrated that MIBG-induced vasoactive
effects can be antagonized by the 5-HT receptor blocker cypro-
heptadine (Kuin et al, 1998).
In conclusion, repeated oral administration of MIBG is a
promising alternative for long-term palliation of the carcinoid
syndrome without the need for hospitalization.
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